- Home
- SNAX vs BPTH Comparison
SNAX vs BPTH Comparison
Compare SNAX & BPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAX
- BPTH
- Stock Information
- Founded
- SNAX 2017
- BPTH 2007
- Country
- SNAX United States
- BPTH United States
- Employees
- SNAX N/A
- BPTH N/A
- Industry
- SNAX Packaged Foods
- BPTH Biotechnology: Pharmaceutical Preparations
- Sector
- SNAX Consumer Staples
- BPTH Health Care
- Exchange
- SNAX Nasdaq
- BPTH Nasdaq
- Market Cap
- SNAX 3.1M
- BPTH 2.8M
- IPO Year
- SNAX N/A
- BPTH N/A
- Fundamental
- Price
- SNAX $0.63
- BPTH $0.70
- Analyst Decision
- SNAX
- BPTH Strong Buy
- Analyst Count
- SNAX 0
- BPTH 2
- Target Price
- SNAX N/A
- BPTH $30.00
- AVG Volume (30 Days)
- SNAX 57.4K
- BPTH 107.0K
- Earning Date
- SNAX 11-13-2024
- BPTH 11-15-2024
- Dividend Yield
- SNAX N/A
- BPTH N/A
- EPS Growth
- SNAX N/A
- BPTH N/A
- EPS
- SNAX N/A
- BPTH N/A
- Revenue
- SNAX $19,364,939.00
- BPTH N/A
- Revenue This Year
- SNAX $30.31
- BPTH N/A
- Revenue Next Year
- SNAX N/A
- BPTH N/A
- P/E Ratio
- SNAX N/A
- BPTH N/A
- Revenue Growth
- SNAX N/A
- BPTH N/A
- 52 Week Low
- SNAX $0.55
- BPTH $0.59
- 52 Week High
- SNAX $2.95
- BPTH $12.00
- Technical
- Relative Strength Index (RSI)
- SNAX 26.04
- BPTH 40.01
- Support Level
- SNAX $0.55
- BPTH $0.64
- Resistance Level
- SNAX $0.94
- BPTH $0.71
- Average True Range (ATR)
- SNAX 0.07
- BPTH 0.10
- MACD
- SNAX -0.02
- BPTH 0.01
- Stochastic Oscillator
- SNAX 22.88
- BPTH 28.74
About SNAX Stryve Foods Inc.
Stryve Foods Inc is a healthy snacking company that manufactures, markets, and sells differentiated healthy snacking products. The company offers convenient snacks that are lower in sugar and carbohydrates and higher in protein than other snacks.
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.